| abstract |
The disclosure herein is compositions and methods for detecting biomolecules and biomarkers associated with prostate cancer. The disclosure herein provides compositions and methods for detecting biomolecules and biomarkers associated with castration resistant prostate cancer, wherein such biomolecules and biomarkers are prostate cancer. Includes androgen receptor splice variants that can be used to develop effective treatment regimens for patients. The disclosure herein is a method of using biomolecules and biomarkers associated with androgen receptor splice variants to assess therapeutic resistance to drugs such as enzalutamide and abiraterone. [Selection] Figure 1A |